Taliaz is an Israeli mental health startup which uses artificial intelligence to create new products for the treatment of mental health issues. The company was just awarded $3 million from the EU Horizon 2020 Grant.
Founded in 2012, Taliaz currently has about $4.1 million in funding.
So AI can even be used to treat mental health now. No it’s not what you think. This is not about having a computerized hologram serve as your therapist or using some kind of high tech brain implants to treat schizophrenics or people who suffer from bipolar disorder.
Here the idea is that smart computers can be used to assist doctors and therapists. Programs will compile data and make recommendations. But the human being who treats a patient will still make the decisions.
Taliaz offers PREDICTIX, a CE-registered product that provides an advanced decision support software for psychiatrists and general practitioners.
The company says that by harnessing artificial intelligence, PREDICTIX can enable effective and rapid patient assessment, improved prescribing precision and management for a wide range of mental health conditions. Taliaz boasts that in the field of depression, the PREDICTIX Genetics and PREDICTIX Digital products can improve today’s prescribing accuracy by up to 47%.
Taliaz featured in @MobiHealthNews. Read more about our $2.7 Million EU Horizon 2020 grant funding and why this matters for the #mentalhealth sector. Thank you @SMageit.#AI #PREDICTIX #precisionmedicine https://t.co/jbivckV2s4
— Taliaz (@taliaz_health) November 11, 2020
Dekel Taliaz, CEO and Co-founder of Taliaz said, “We are excited to receive the prestigious Horizon 2020 grant. The funding from the European Commission endorses the strong science behind our approach. This is especially important as mental health rises across the globe during the COVID-19 pandemic. The funds will support our mission to improve patient wellbeing and reduce associated costs by ensuring every patient gets the right mental health treatment, the first time.”
Taliaz is currently in the process of raising a further round of investment to accelerate and expand commercial efforts with health care systems, payers, providers, DNA laboratories and telemedicine providers globally.